New forms of technology utilizing the antibody-drug conjugate (ADC) are global trends. One such form is the degrader-antibody conjugate (DAC), a conjugate with the ADC merged with targeted protein degradation (TPD).

According to industry sources on the 27th, Biotech companies, including Orum Therapeutics, Nurix Therapeutics, Prelude Therapeutics, and C4 Therapeutics, are developing DAC. Global pharmaceutical companies are investing in major biotech companies due to the potential for commercialization of DAC.

ADC is a novel anticancer drug that connects an antibody, which binds to specific antigens on the surface of cancer cells, with a cytotoxic drug linked by a linker. ADCs take advantage o